Maximising data capture in obesity trials - Pharmaceutical Technology

Learn how ICON’s pragmatic DXA strategy captures complete visceral fat datasets, preventing “silent attrition” and protecting trial integrity, timelines, and budgets. Scale GLP-1 obesity trials without losing DXA data. Credit via Shutterstock. Global obesity trials are scaling fast with GLP‑1 therapies, making complete data capture essential to preserve scientific integrity and timelines. ICON implemented a pragmatic DXA strategy—modified hand positioning and a dual‑scan workflow with centralized review—that preserved full visceral fat datasets, preventing “silent attrition” from incomplete imaging. Obesity trials are scaling rapidly. With the rise of GLP-1 therapies like semaglutide and tirzepatide, sponsors are launching global studies with thousands…

Jay Haddow · 2026-05-29

Learn how ICON’s pragmatic DXA strategy captures complete visceral fat datasets, preventing “silent attrition” and protecting trial integrity, timelines, and budgets.

Source: Pharmaceutical Technology